SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Gates Foundation

CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100

Reported Value
$60M
Q2 2024
Positions
6
Filings on Record
19
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Gates Foundation reported $60M in U.S.-listed holdings across 6 positions for Q2 2024.

The portfolio is heavily concentrated: IMCR alone accounts for 32.7% of reported value.

Compared with Q1 2024, the fund opened 0 new positions and exited 2.

Portfolio Metrics

Turnover
0.0%
vs prior filed quarter
Largest Position
+32.7%
Immunocore

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $438MQ4 ’20Q1 ’21: $656MQ2 ’21: $692MQ2 ’21Q3 ’21: $342MQ4 ’21: $330MQ4 ’21Q1 ’22: $186MQ2 ’22: $130MQ2 ’22Q3 ’22: $127MQ4 ’22: $130MQ4 ’22Q1 ’23: $113MQ2 ’23: $126MQ2 ’23Q3 ’23: $84MQ4 ’23: $90MQ4 ’23Q1 ’24: $84MQ2 ’24: $60MQ2 ’24Q3 ’24: $44Mfilingsflow.com

Portfolio Composition

By security type
ADR: 66.3%Common Stock: 24.6%Other: 9.1%
  • ADR · 66.3% · $40M
  • Common Stock · 24.6% · $15M
  • Other · 9.1% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LUMIRADX LTDSOLD OUT14.29M0$142,857$0
ATRECA INCSOLD OUT912.6K0$73,011$0
IMCRIMMUNOCORE HLDGS PLCHELD+0576.9K$18M$20M
VIRVIR BIOTECHNOLOGY INCHELD+01.56M$2M$14M
BNTXBIONTECH SEHELD+0148.7K$2M$12M
CUREVAC N VHELD+01.60M$1M$5M
EXSCIENTIAHELD+01.59M$986,363$8M
BFLYBUTTERFLY NETWORK INCHELD+01.01M$242,640$849,243

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

6 positions
#IssuerClass% PortfolioValueShares
1IMCRIMMUNOCORE HLDGS PLChistory →ADS32.71%$20M576.9K
2VIRVIR BIOTECHNOLOGY INChistory →COM23.22%$14M1.56M
3BNTXBIONTECH SEhistory →SPONSORED ADS19.99%$12M148.7K
4EXSCIENTIAADS13.57%$8M1.59M
5CUREVAC N VCOM9.09%$5M1.60M
6BFLYBUTTERFLY NETWORK INChistory →COM CL A1.42%$849,2431.01M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$44M5Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$60M6Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$84M8May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$90M8Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$84M9Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$126M9Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$113M9May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$130M9Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$127M10Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$130M9Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$186M11May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$330M11Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M10Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$692M8Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$656M7May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$438M5Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.